Poniard Pharmaceuticals Inc. (NASDAQ: PARD), $2.61, +0.47, 21.96%, traded the day away between 2.17 and 2.70, closing on gains of 21.96%. Poniard Pharmaceuticals is a biopharmaceutical company with its main focus on the development and commercialization of cancer therapy products. Poniard works with picoplatin as a preferred platinum agent in the treatment of solid tumor malignancies. The company listed its targets for 2010 for Picoplatin as completing discussions with the FDA for a regulatory path forward for picoplatin, among others.
Es ist nicht die Kunst eine gute Aktie von der anderen zu unterscheiden, nein es ist das schöne Gefühl!
lg, ice